315 related articles for article (PubMed ID: 17937915)
21. Molecular dynamics simulation of the ligand binding domain of farnesoid X receptor. Insights into helix-12 stability and coactivator peptide stabilization in response to agonist binding.
Costantino G; Entrena-Guadix A; Macchiarulo A; Gioiello A; Pellicciari R
J Med Chem; 2005 May; 48(9):3251-9. PubMed ID: 15857131
[TBL] [Abstract][Full Text] [Related]
22. 2D QSAR of PPARgamma agonist binding and transactivation.
Rücker C; Scarsi M; Meringer M
Bioorg Med Chem; 2006 Aug; 14(15):5178-95. PubMed ID: 16650995
[TBL] [Abstract][Full Text] [Related]
23. Structure-based pharmacophore screening for natural-product-derived PPARgamma agonists.
Tanrikulu Y; Rau O; Schwarz O; Proschak E; Siems K; Müller-Kuhrt L; Schubert-Zsilavecz M; Schneider G
Chembiochem; 2009 Jan; 10(1):75-8. PubMed ID: 19067454
[No Abstract] [Full Text] [Related]
24. Structural basis for PPARγ transactivation by endocrine-disrupting organotin compounds.
Harada S; Hiromori Y; Nakamura S; Kawahara K; Fukakusa S; Maruno T; Noda M; Uchiyama S; Fukui K; Nishikawa J; Nagase H; Kobayashi Y; Yoshida T; Ohkubo T; Nakanishi T
Sci Rep; 2015 Feb; 5():8520. PubMed ID: 25687586
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, and structural analysis of phenylpropanoic acid-type PPARγ-selective agonists: discovery of reversed stereochemistry-activity relationship.
Ohashi M; Oyama T; Nakagome I; Satoh M; Nishio Y; Nobusada H; Hirono S; Morikawa K; Hashimoto Y; Miyachi H
J Med Chem; 2011 Jan; 54(1):331-41. PubMed ID: 21128600
[TBL] [Abstract][Full Text] [Related]
26. Ligand and receptor dynamics contribute to the mechanism of graded PPARγ agonism.
Hughes TS; Chalmers MJ; Novick S; Kuruvilla DS; Chang MR; Kamenecka TM; Rance M; Johnson BA; Burris TP; Griffin PR; Kojetin DJ
Structure; 2012 Jan; 20(1):139-50. PubMed ID: 22244763
[TBL] [Abstract][Full Text] [Related]
27. Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study.
Salam NK; Huang TH; Kota BP; Kim MS; Li Y; Hibbs DE
Chem Biol Drug Des; 2008 Jan; 71(1):57-70. PubMed ID: 18086153
[TBL] [Abstract][Full Text] [Related]
28. Different structures of the two peroxisome proliferator-activated receptor gamma (PPARγ) ligand-binding domains in homodimeric complex with partial agonist, but not full agonist.
Ohashi M; Oyama T; Miyachi H
Bioorg Med Chem Lett; 2015 Jul; 25(13):2639-44. PubMed ID: 25987371
[TBL] [Abstract][Full Text] [Related]
29. Development of docking-based 3D-QSAR models for PPARgamma full agonists.
Guasch L; Sala E; Valls C; Mulero M; Pujadas G; Garcia-Vallvé S
J Mol Graph Model; 2012 Jun; 36():1-9. PubMed ID: 22503857
[TBL] [Abstract][Full Text] [Related]
30. Mechanism of peroxisome proliferator-activated receptor gamma (PPARγ) transactivation by hesperetin glucuronides is distinct from that by a thiazolidine-2,4-dione agent.
Gamo K; Shiraki T; Matsuura N; Miyachi H
Chem Pharm Bull (Tokyo); 2014; 62(5):491-3. PubMed ID: 24789933
[TBL] [Abstract][Full Text] [Related]
31. 1,3-Diphenyl-1H-pyrazole derivatives as a new series of potent PPARγ partial agonists.
Choi J; Park Y; Lee HS; Yang Y; Yoon S
Bioorg Med Chem; 2010 Dec; 18(23):8315-23. PubMed ID: 21030263
[TBL] [Abstract][Full Text] [Related]
32. Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) γ activators and pan-PPAR partial agonists.
Liberato MV; Nascimento AS; Ayers SD; Lin JZ; Cvoro A; Silveira RL; Martínez L; Souza PC; Saidemberg D; Deng T; Amato AA; Togashi M; Hsueh WA; Phillips K; Palma MS; Neves FA; Skaf MS; Webb P; Polikarpov I
PLoS One; 2012; 7(5):e36297. PubMed ID: 22649490
[TBL] [Abstract][Full Text] [Related]
33. Discovery of a novel selective PPARgamma modulator from (-)-Cercosporamide derivatives.
Furukawa A; Arita T; Satoh S; Wakabayashi K; Hayashi S; Matsui Y; Araki K; Kuroha M; Ohsumi J
Bioorg Med Chem Lett; 2010 Apr; 20(7):2095-8. PubMed ID: 20219371
[TBL] [Abstract][Full Text] [Related]
34. Identification of novel PPARalpha ligands by the structural modification of a PPARgamma ligand.
Usui S; Fujieda H; Suzuki T; Yoshida N; Nakagawa H; Miyata N
Bioorg Med Chem Lett; 2006 Jun; 16(12):3249-54. PubMed ID: 16621530
[TBL] [Abstract][Full Text] [Related]
35. Ligand entry pathways in the ligand binding domain of PPARγ receptor.
Aci-Sèche S; Genest M; Garnier N
FEBS Lett; 2011 Aug; 585(16):2599-603. PubMed ID: 21782815
[TBL] [Abstract][Full Text] [Related]
36. Vitamin D receptor: ligand recognition and allosteric network.
Yamamoto K; Abe D; Yoshimoto N; Choi M; Yamagishi K; Tokiwa H; Shimizu M; Makishima M; Yamada S
J Med Chem; 2006 Feb; 49(4):1313-24. PubMed ID: 16480267
[TBL] [Abstract][Full Text] [Related]
37. Quinoline-based derivatives of pirinixic acid as dual PPAR alpha/gamma agonists.
Popescu L; Rau O; Böttcher J; Syha Y; Schubert-Zsilavecz M
Arch Pharm (Weinheim); 2007 Jul; 340(7):367-71. PubMed ID: 17610302
[TBL] [Abstract][Full Text] [Related]
38. Small-angle X-ray scattering studies on structures of an estrogen-related receptor alpha ligand binding domain and its complexes with ligands and coactivators.
Jin KS; Park JK; Yoon J; Rho Y; Kim JH; Kim EE; Ree M
J Phys Chem B; 2008 Aug; 112(32):9603-12. PubMed ID: 18646811
[TBL] [Abstract][Full Text] [Related]
39. Structural review of PPARγ in complex with ligands: Cartesian- and dihedral angle principal component analyses of X-ray crystallographic data.
Kaupang Å; Laitinen T; Poso A; Hansen TV
Proteins; 2017 Sep; 85(9):1684-1698. PubMed ID: 28543443
[TBL] [Abstract][Full Text] [Related]
40. Peroxisome proliferator-activated receptor gamma (PPARγ) has multiple binding points that accommodate ligands in various conformations: Structurally similar PPARγ partial agonists bind to PPARγ LBD in different conformations.
Ohashi M; Gamo K; Oyama T; Miyachi H
Bioorg Med Chem Lett; 2015 Jul; 25(14):2758-62. PubMed ID: 26025876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
